- Home
- TMHC vs BPMC Comparison
TMHC vs BPMC Comparison
Compare TMHC & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMHC
- BPMC
- Stock Information
- Founded
- TMHC 1936
- BPMC 2008
- Country
- TMHC United States
- BPMC United States
- Employees
- TMHC N/A
- BPMC N/A
- Industry
- TMHC Homebuilding
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- TMHC Consumer Discretionary
- BPMC Health Care
- Exchange
- TMHC Nasdaq
- BPMC Nasdaq
- Market Cap
- TMHC 7.1B
- BPMC 7.0B
- IPO Year
- TMHC 2013
- BPMC 2015
- Fundamental
- Price
- TMHC $60.80
- BPMC $92.25
- Analyst Decision
- TMHC Buy
- BPMC Buy
- Analyst Count
- TMHC 8
- BPMC 19
- Target Price
- TMHC $83.50
- BPMC $123.61
- AVG Volume (30 Days)
- TMHC 1.1M
- BPMC 1.1M
- Earning Date
- TMHC 02-12-2025
- BPMC 02-13-2025
- Dividend Yield
- TMHC N/A
- BPMC N/A
- EPS Growth
- TMHC 18.48
- BPMC N/A
- EPS
- TMHC 8.27
- BPMC N/A
- Revenue
- TMHC $8,168,136,000.00
- BPMC $508,824,000.00
- Revenue This Year
- TMHC $4.10
- BPMC $44.29
- Revenue Next Year
- TMHC $5.80
- BPMC $32.49
- P/E Ratio
- TMHC $7.35
- BPMC N/A
- Revenue Growth
- TMHC 10.11
- BPMC 104.04
- 52 Week Low
- TMHC $53.17
- BPMC $80.68
- 52 Week High
- TMHC $75.49
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- TMHC 39.56
- BPMC 34.05
- Support Level
- TMHC $61.51
- BPMC $90.84
- Resistance Level
- TMHC $66.17
- BPMC $96.78
- Average True Range (ATR)
- TMHC 1.88
- BPMC 4.34
- MACD
- TMHC -0.29
- BPMC -2.26
- Stochastic Oscillator
- TMHC 4.87
- BPMC 5.64
About TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West and Financial Services. The majority of the company's revenue is derived from its East Segment.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.